Identification of drug-like molecules targeting the ATPase activity of dynamin-like EHD4.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 09 04 2024
accepted: 13 07 2024
medline: 29 7 2024
pubmed: 29 7 2024
entrez: 29 7 2024
Statut: epublish

Résumé

Eps15 (epidermal growth factor receptor pathway substrate 15) homology domain-containing proteins (EHDs) comprise a family of eukaryotic dynamin-related ATPases that participate in various endocytic membrane trafficking pathways. Dysregulation of EHDs function has been implicated in various diseases, including cancer. The lack of small molecule inhibitors which acutely target individual EHD members has hampered progress in dissecting their detailed cellular membrane trafficking pathways and their function during disease. Here, we established a Malachite green-based assay compatible with high throughput screening to monitor the liposome-stimulated ATPase of EHD4. In this way, we identified a drug-like molecule that inhibited EHD4's liposome-stimulated ATPase activity. Structure activity relationship (SAR) studies indicated sites of preferred substitutions for more potent inhibitor synthesis. Moreover, the assay optimization in this work can be applied to other dynamin family members showing a weak and liposome-dependent nucleotide hydrolysis activity.

Identifiants

pubmed: 39074100
doi: 10.1371/journal.pone.0302704
pii: PONE-D-24-14329
doi:

Substances chimiques

Liposomes 0
Adenosine Triphosphatases EC 3.6.1.-
Dynamins EC 3.6.5.5
malachite green 12058M7ORO
Rosaniline Dyes 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0302704

Informations de copyright

Copyright: © 2024 Mohd et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Saif Mohd (S)

Structural Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Institute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.

Andreas Oder (A)

Screening Unit, Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany.

Edgar Specker (E)

Screening Unit, Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany.

Martin Neuenschwander (M)

Screening Unit, Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany.

Jens Peter Von Kries (JP)

Screening Unit, Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany.

Oliver Daumke (O)

Structural Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Institute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH